StimCardio Medical, Inc.

Based in the US, StimCardio Medical, Inc. , operates as a clinical-stage medical device company focused on non-invasive cardiac rhythm management solutions. Based in Los Angeles, the US and founded in 2025, StimCardio Medical, Inc. develops innovative solutions for cardiac rhythm disorders.

The company is working on a wearable neuromodulation platform to manage atrial fibrillation. In November 2026, StimCardio Medical, Inc. raised USD 24. 95 mn in venture funding from unspecified investors.

StimCardio Medical is focused on advancing cardiac care through its core product, Rhyvive™, a non-invasive, wrist-worn wearable neuromodulation device. This platform integrates continuous physiological sensing and personalized therapy, specifically targeting atrial fibrillation (AF). Rhyvive™ utilizes advanced technology to continuously monitor cardiac and autonomic signals, employing both optical and electrical (EKG) sensors to analyze physiological data, ultimately delivering tailored peripheral neuromodulation. The device is designed for everyday use, with the potential to significantly improve heart-brain communication while reducing the burden of AF.

StimCardio aims to serve a global market, addressing the needs of patients suffering from atrial fibrillation and related cardiovascular issues, thereby enhancing their overall quality of life. The revenue structure of StimCardio Medical primarily involves the deployment of its flagship product, Rhyvive™, through a subscription-based model that may include partnerships with healthcare providers and clinical institutions. The business model entails direct transactions with end-users—patients—and collaborations with healthcare providers who integrate this technology into their cardiac care protocols. StimCardio may leverage cloud-based services for real-time data analysis, enhancing the user experience and enabling ongoing patient engagement.

Such a model is expected to facilitate multiple revenue streams while fostering a continuous relationship with clients and patients as they utilize the personalized neuromodulation therapy for atrial fibrillation management. The company plans to expand its product offerings and enhance its technology to improve patient outcomes in cardiac care. Current initiatives include further development of the Rhyvive™ platform and exploring partnerships to broaden its market reach.